Over expression of a synthetic gene encoding interferon lambda using relative synonymous Codon usage bias in Escherichia coli

被引:0
作者
Akhtar, Hashaam [1 ]
Akhtar, Samar [2 ]
Jan, Syed Umer [3 ]
Khan, Azka [1 ]
Zaidi, Najam Us Sahar Sadaf [1 ]
Qadri, Ishtiaq [4 ]
机构
[1] Natl Univ Sci & Technol, Atta Ur Rahman Sch Appl Biosci, Islamabad, Pakistan
[2] Riphah Int Univ, Riphah Inst Pharmaceut Sci, Islamabad, Pakistan
[3] Univ Balochistan, Dept Pharm, Quetta, Pakistan
[4] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21413, Saudi Arabia
关键词
Relative synonymous codon usage (RSCU) Interferon Lambda; over-expression; CHRONIC HEPATITIS-C; SACCHAROMYCES-CEREVISIAE; ADAPTATION INDEX; VIRUS; PROTEINS; TRANSLATION; PERSPECTIVE; ORGANISMS; CLEARANCE; INFECTION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interferon Lambda (IFN-lambda) is a type III interferon which belongs to a novel family of cytokines and possesses antiviral and antitumor properties. It is unique in its own class of cytokines; because of the specificity towards its heterodimer receptors and its structural similarities with cytokines of other classes. This renders IFN-lambda a better choice for the treatment against many diseases including viral hepatitis and human coronavirus (HCoV-EMC). The present study describes a computational approach known as relative synonymous codon usage (RSCU); used to enhance the expression of IFN-lambda protein in a eukaryotic expression system. Manually designed and commercially synthesized IFN-lambda gene was cloned into pET-22b expression plasmid under the control of inducible T7-lac promoter. Maximum levels of IFN-lambda, expression was observed with 0.4 mM IPTG in transformed E. coli incubated for 4 hours in LB medium. Higher concentrations of IPTG had no or negative effect on the expression of IFN-lambda. This synthetically over expressed IFN-lambda can be tested as a targeted treatment option for viral hepatitis after purification.
引用
收藏
页码:1181 / 1188
页数:8
相关论文
共 61 条
[1]   Protease inhibitors: Silver bullets for chronic hepatitis C infection? [J].
Alkhouri, Naim ;
Zein, Nizar N. .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2012, 79 (03) :213-222
[2]  
[Anonymous], 2002, Gastroenterology, V123, P2082, DOI 10.1053/gast.2002.1232082
[3]  
Baker D E, 2001, Rev Gastroenterol Disord, V1, P87
[4]  
Barnard D L, 2001, Curr Opin Investig Drugs, V2, P1530
[5]   Antiproliferative Properties of Type I and Type II Interferon [J].
Bekisz, Joseph ;
Baron, Samuel ;
Balinsky, Corey ;
Morrow, Angel ;
Zoon, Kathryn C. .
PHARMACEUTICALS, 2010, 3 (04) :994-1015
[6]   Interferon: The pathways of discovery - I. Molecular and cellular aspects [J].
Billiau, Alfons .
CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (05) :381-409
[7]   Interferons at age 50: past, current and future impact on biomedicine [J].
Borden, Ernest C. ;
Sen, Ganes C. ;
Uze, Gilles ;
Silverman, Robert H. ;
Ransohoff, Richard M. ;
Foster, Graham R. ;
Stark, George R. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :975-990
[8]   Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C [J].
Buti, M ;
San Miguel, R ;
Brosa, M ;
Cabasés, JM ;
Medina, M ;
Casado, MA ;
Fosbrook, L ;
Esteban, R .
JOURNAL OF HEPATOLOGY, 2005, 42 (05) :639-645
[9]   LACTOCOCCUS-LACTIS GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE, GAP - FURTHER EVIDENCE FOR STRONGLY BIASED CODON USAGE IN GLYCOLYTIC PATHWAY GENES [J].
CANCILLA, MR ;
HILLIER, AJ ;
DAVIDSON, BE .
MICROBIOLOGY-UK, 1995, 141 :1027-1036
[10]   Interferon, a growing cytokine family: 50 years of interferon research [J].
Chelbi-Alix, Mounira K. ;
Wietzerbin, Juana .
BIOCHIMIE, 2007, 89 (6-7) :713-718